TG THERAPEUTICS, INC. Deferred Compensation Liability, Current
TG THERAPEUTICS, INC. (TGTX) had Deferred Compensation Liability, Current of $35.20 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredCompensationLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Deferred Compensation Liability, Current $35.20M.
- 2026-03-31: Deferred Compensation Liability, Current $18.66M.
- 2025-12-31: Deferred Compensation Liability, Current $21.85M.
- 2025-09-30: Deferred Compensation Liability, Current $15.01M.
| Period end | Deferred Compensation Liability, Current |
|---|---|
| 2026-06-30 | $35.20M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $18.66M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $21.85M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $15.01M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $10.61M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $5.13M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $15.19M 10-K · filed 2026-02-27 |
| 2024-09-30 | $10.09M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $6.35M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $3.60M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $12.17M 10-K · filed 2025-03-03 |
| 2023-09-30 | $8.34M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $6.64M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $3.22M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $8.43M 10-K · filed 2024-02-29 |
| 2022-09-30 | $4.30M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $2.88M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.62M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $10.17M 10-K · filed 2023-03-01 |
| 2021-09-30 | $12.86M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $8.51M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $3.54M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $8.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $5.07M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $3.44M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.37M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.80M 10-K · filed 2021-03-01 |
| 2019-09-30 | $3.02M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.71M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $854.00K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $2.26M 10-K · filed 2020-03-02 |
| 2018-09-30 | $2.08M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $1.18M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $456.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $1.80M 10-K · filed 2019-03-01 |
| 2017-09-30 | $1.28M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $896.80K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $483.56K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $1.39M 10-K · filed 2018-03-15 |
| 2016-09-30 | $1.06M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $796.38K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $449.13K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $818.47K 10-K · filed 2017-03-16 |
| 2015-09-30 | $768.75K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $506.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $248.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $702.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | $599.08K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $395.50K 10-Q · filed 2014-07-24 |
| 2014-03-31 | $197.25K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $532.50K 10-K · filed 2015-03-16 |
| 2013-09-30 | $350.00K 10-Q · filed 2013-11-14 |
| 2013-06-30 | $232.75K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $115.50K 10-Q · filed 2013-05-14 |
| 2012-12-31 | $145.00K 10-K · filed 2014-03-07 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |